Search
Close this search box.

Getting under
the skin of drug
delivery.

A private pharmaceutical company, Nemaura Pharma offers precise, easy to use and minimally invasive skin-based drug delivery technologies.

Our technologies can lead to significantly improved healthcare and patient management by increasing the effectiveness and safety of therapeutic drugs, while also reducing complications due to patient error or non-compliance.

Key Facts

Many biologics and new drugs must be administered with needles and syringes
Self-administration is difficult and painful, poor patient compliance leads to hospitalisation

Our systems improve drug delivery and enhance compliance in a minimally invasive format.

According to QY Research Medical, the Transdermal Drug Delivery market is poised to grow to over $87 Billion by 2030
Research by Frost & Sullivan has revealed a growing desire for new drug delivery forms
Both patients and physicians view skin drug delivery systems as their method of choice.
$2.6bn is the estimated cost of developing and bringing a new drug to market
Developing a superior delivery formulation for an existing drug can take just four years and less
There is a huge opportunity to differentiate old drugs by incorporating superior delivery advantages with tangible benefits.

Nemaura Pharma is ISO9001 and ISO13485 accredited.

We have an in-house clean room for cGMP manufacture of investigational medicinal products, under aseptic conditions.

We also have an in-house design and prototyping facility for medical devices, using medical grade materials, and possess a Home office license for controlled drugs.

Our partners for commercial manufacture include state-of-the-art facilities for transdermal patch manufacture.

Quality as
standard

TECHNOLOGIES & LICENSING

To find out about Nemaura Pharma, our technologies and how you can work with us, please contact us.
Contact us

Stay Informed

Subscribe here to get company news and updates about our technologies.
Copyright © 2024 Nemaura Pharma. All rights reserved.